Additional lock-up agreements have been signed by Chairman of the board and management
DanCann Pharma A/S (” DanCann Pharma” or the “Company”) hereby announces that additional board members and management have been allotted units in the IPO. DanCann Pharma’s Chairman of the Board, Magnus Østergaard Dahlmann, Chief Commercial Officer, John Morell Frellsen (who works for the Company as a consultant and is thereby not part of the Company’s registered executive management) and Chief Financial Officer, Mads Møller Kristensen (’the “Subscribers’’) that subscribed for units in the fully subscribed IPO have now been allotted units after the subscription period ended on October 23[rd]